PT1572196E - Combinação de um inibidor da dpp-iv e um composto ppar alfa - Google Patents
Combinação de um inibidor da dpp-iv e um composto ppar alfa Download PDFInfo
- Publication number
- PT1572196E PT1572196E PT03785782T PT03785782T PT1572196E PT 1572196 E PT1572196 E PT 1572196E PT 03785782 T PT03785782 T PT 03785782T PT 03785782 T PT03785782 T PT 03785782T PT 1572196 E PT1572196 E PT 1572196E
- Authority
- PT
- Portugal
- Prior art keywords
- dpp
- inhibitor
- combination
- conditions
- ppar
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43219202P | 2002-12-10 | 2002-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1572196E true PT1572196E (pt) | 2008-11-20 |
Family
ID=32507865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT03785782T PT1572196E (pt) | 2002-12-10 | 2003-12-09 | Combinação de um inibidor da dpp-iv e um composto ppar alfa |
Country Status (13)
Country | Link |
---|---|
US (2) | US20060111428A1 (pt) |
EP (1) | EP1572196B1 (pt) |
JP (1) | JP2006512334A (pt) |
CN (1) | CN100348189C (pt) |
AT (1) | ATE404191T1 (pt) |
AU (1) | AU2003294824A1 (pt) |
BR (1) | BR0317028A (pt) |
CA (1) | CA2505771A1 (pt) |
DE (1) | DE60322944D1 (pt) |
ES (1) | ES2311117T3 (pt) |
HK (1) | HK1085377A1 (pt) |
PT (1) | PT1572196E (pt) |
WO (1) | WO2004052362A1 (pt) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
AU2005259864A1 (en) * | 2004-06-30 | 2006-01-12 | Combinatorx, Incorporated | Methods and reagents for the treatment of metabolic disorders |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EP1785133A1 (en) * | 2005-11-10 | 2007-05-16 | Laboratoires Fournier S.A. | Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
CN101437823B (zh) | 2006-05-04 | 2014-12-10 | 勃林格殷格翰国际有限公司 | 多晶型 |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
KR20110067096A (ko) | 2008-09-10 | 2011-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 및 관련 상태를 치료하기 위한 병용 요법 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
KR101054911B1 (ko) | 2008-10-17 | 2011-08-05 | 동아제약주식회사 | 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 |
KR20110103968A (ko) | 2008-12-23 | 2011-09-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 유기 화합물의 염 형태 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
EA034869B1 (ru) | 2009-11-27 | 2020-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |
WO2011080276A1 (en) | 2009-12-29 | 2011-07-07 | Genfit | Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative |
BR112012025592A2 (pt) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos |
BR112012028136A2 (pt) | 2010-05-05 | 2016-08-09 | Boehringer Ingelheim Int | terapia de combinaçao |
KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
PE20131371A1 (es) | 2010-09-22 | 2013-11-25 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
WO2012099915A1 (en) * | 2011-01-19 | 2012-07-26 | Hongwen Zhu | Thiazolidine derivatives and their therapeutic use |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP2731947B1 (en) | 2011-07-15 | 2019-01-16 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体 |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
CN104529857B (zh) * | 2015-01-13 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 卤代金刚烷酰胺类衍生物、其制备方法和用途 |
WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
EP3606527A1 (en) | 2017-04-03 | 2020-02-12 | Coherus Biosciences, Inc. | Ppar-gamma agonist for treatment of progressive supranuclear palsy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2052014A1 (en) * | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
PT1741447E (pt) * | 2000-01-21 | 2013-12-11 | Novartis Ag | Combinações que compreendem o inibidor da dipeptidilpeptidase-iv |
EP1259494A4 (en) * | 2000-02-18 | 2004-09-15 | Merck & Co Inc | ARYLOXY ACETIC ACIDS FOR DIABETES AND LIPID DISEASES |
US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
AU2002222550A1 (en) * | 2000-11-29 | 2002-06-11 | Kyorin Pharmaceutical Co. Ltd. | Substituted carboxylic acid derivatives |
CA2437118A1 (en) * | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
US7026316B2 (en) * | 2001-03-27 | 2006-04-11 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
US7253172B2 (en) * | 2001-06-20 | 2007-08-07 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
TW200303742A (en) * | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
-
2003
- 2003-12-09 AU AU2003294824A patent/AU2003294824A1/en not_active Abandoned
- 2003-12-09 DE DE60322944T patent/DE60322944D1/de not_active Expired - Lifetime
- 2003-12-09 BR BR0317028-4A patent/BR0317028A/pt unknown
- 2003-12-09 WO PCT/EP2003/013963 patent/WO2004052362A1/en active IP Right Grant
- 2003-12-09 ES ES03785782T patent/ES2311117T3/es not_active Expired - Lifetime
- 2003-12-09 CA CA002505771A patent/CA2505771A1/en not_active Abandoned
- 2003-12-09 US US10/537,870 patent/US20060111428A1/en not_active Abandoned
- 2003-12-09 EP EP03785782A patent/EP1572196B1/en not_active Expired - Lifetime
- 2003-12-09 CN CNB2003801052605A patent/CN100348189C/zh not_active Expired - Fee Related
- 2003-12-09 AT AT03785782T patent/ATE404191T1/de active
- 2003-12-09 JP JP2004558050A patent/JP2006512334A/ja active Pending
- 2003-12-09 PT PT03785782T patent/PT1572196E/pt unknown
-
2006
- 2006-03-02 HK HK06102771.5A patent/HK1085377A1/xx not_active IP Right Cessation
-
2008
- 2008-08-12 US US12/190,149 patent/US20080300293A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2311117T3 (es) | 2009-02-01 |
WO2004052362A1 (en) | 2004-06-24 |
HK1085377A1 (en) | 2006-08-25 |
ATE404191T1 (de) | 2008-08-15 |
JP2006512334A (ja) | 2006-04-13 |
AU2003294824A1 (en) | 2004-06-30 |
BR0317028A (pt) | 2005-10-25 |
CA2505771A1 (en) | 2004-06-24 |
CN1720042A (zh) | 2006-01-11 |
CN100348189C (zh) | 2007-11-14 |
EP1572196A1 (en) | 2005-09-14 |
US20060111428A1 (en) | 2006-05-25 |
US20080300293A1 (en) | 2008-12-04 |
DE60322944D1 (de) | 2008-09-25 |
EP1572196B1 (en) | 2008-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1085377A1 (en) | Combination of a dpp-iv inhibitor and a ppar-alpha compound | |
MX2007004934A (es) | Combinacion de inhibidor de dpp-iv, anti-diabetico de ppar, y metformina. | |
DE60301491D1 (en) | Acc-hemmer | |
WO2001081310A8 (en) | 1-aroyl-piperidinyl benzamidines | |
EP1602370A3 (en) | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases | |
WO2001062266A3 (en) | Use of dpp-iv inhibitors for the treatment of diabetes | |
IL187005A0 (en) | Diacylglycerol acyltransferase inhibitors | |
WO2003059291A3 (en) | Treatment of bone disorders with skeletal anabolic drugs | |
EP2325651A3 (en) | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | |
EP2277512A3 (en) | Pharmaceutical compositions and dosage forms of thalidomide | |
HK1082733A1 (en) | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) | |
NZ572049A (en) | Method for treatment of constipation-predominant irritable bowel syndrome | |
GEP20074030B (en) | Controlled synthesis of ziprasidone and compositions thereof | |
HK1100559A1 (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | |
WO2004043456A8 (en) | Cholesterol absorption inhibitors for the treatment of demyelination | |
WO2001056573A8 (en) | Use of cox-2 inhibitors as gastroprokinetics | |
DE60215139D1 (en) | Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren | |
RS20060662A (en) | 4-phenyl-pyrimidine-2-carbonitrile derivatives | |
WO2002005642A3 (en) | Synergistic biocidal compositions | |
RU2004104457A (ru) | Композиции, обладающие ингибирующим продуцирование tnf действием, и ингибиторы продуцирования tnf | |
AU2003272945A1 (en) | Composition for preventing/treating the expression of clinical symptom in disease caused by mitochondrial dysfunction | |
WO1999063979A3 (en) | Inhibition of δ-9-desaturase activity by saponins | |
WO2004080373A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) | |
DK1249178T3 (da) | Fremgangsmåde til fremstilling af et hidtil ukendt appetitvækkerprodukt og et produkt fremstillet derved | |
WO2005020898A8 (en) | Methods of reducing visceral fat by increasing levels of insulin-like growth factor-i (igf-i) |